Pharmaceuticals
Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing
* Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. * Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug P...
2024-11-12 21:15
2230
Tsingke Successfully Showcases Innovations at BIO-Europe 2024
BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke
2024-11-12 17:07
1675
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain s...
2024-11-11 21:45
2329
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...
2024-11-11 20:30
2087
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
2024-11-11 08:07
2347
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...
2024-11-08 22:00
3146
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
2024-11-08 20:00
2181
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...
2024-11-08 18:01
2080
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2024-11-08 17:45
1885
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is ...
2024-11-08 11:27
2804
InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN1...
2024-11-08 10:40
2075
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held inHouston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, ...
2024-11-08 08:20
2015
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed ...
2024-11-06 20:00
2063
Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors
SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today announced initial results from its Phase I clinical trial of MHB039A, a novel PD-1 x VEGF bispecific antibod...
2024-11-06 18:00
4225
QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 SITC 39th Annual Meeting
SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅱ Clinical Da...
2024-11-06 13:00
1811
Duoning Biotech announced strategic partnership with Branca Bunús to promote the next generation of transfection reagents
SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents, ...
2024-11-06 09:24
1884
Dong'e Ejiao Continues to Propel Traditional Chinese Medicine onto the Global Stage
Harnessing Tradition and Innovation: Dong'e Ejiao's Seventh Appearance at the CIIE SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- On November 5th, the 7th China International Import Expo (CIIE) opened inShanghai. A key player in China Resources Group's healthcare sector, Dong'e Ejiao Co., Ltd. (hereinaf...
2024-11-05 18:09
2206
J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy
- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST ProfessorJoung Ho Kim join a pioneering collaboration in precision oncology. SEOUL, South Korea, Nov. 5, 2024 /PRNewswire/ -- On November 4, 2024, J INTS BIO hosted a significant MOU signing ceremony at Baek...
2024-11-05 17:38
1513
111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that its release of...
2024-11-04 19:00
2455
111, Inc. Announces Change to Board of Directors
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that Dr. Leon Lian ...
2024-11-04 18:00
2417
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 305 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
